In patients with laBCC previously treated with an HHI,
Secondary endpoints included2
Study 1620 was an open-label, multicenter, phase 2, nonrandomized study that included 132 patients, of whom 84 had locally advanced BCC (laBCC) that had progressed on HHI therapy, were intolerant of prior HHI therapy, had not had an objective respose after 9 months on HHI therapy, or were intolerant of prior HHI therapy. Treatment continued until progression of disease, unacceptable toxicity, or completion of planned treatment.1,2
Study 1620 excluded patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior treatment with anti–PD-1/PD-L1 therapy or other immune checkpoint inhibitor therapy; infection with HIV, hepatitis B or hepatitis C; or Eastern Cooperative Oncology Group Performance Status ≥2.1
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.